



Corporate Summary



- High-performance biomaterials for orthopedic surgery
- Commercial, growth-stage company
- FDA-cleared product portfolio; three distinct platforms
 - TRABEXUS[®] EB[™] – moldable, curable, inductive bone matrix[†]
 - FORTERA[™] – self-setting, injectable bone matrix
 - REGENTO[™] – bone void filler
- Diverse clinical uptake; no device-related adverse events
- FDA & ISO 13485 registered manufacturing facility
- Attractive near-term opportunities for portfolio expansion

[†] Allograft component demonstrated osteoinductivity in athymic mouse model submitted for 510(k). Refer to 510(k) summary K143547. Data on file at Vivorté, Inc.

U.S. Orthopedic Biomaterials Market




- Implantable materials used to "fill holes" in skeleton as the result of trauma, surgery or disease
- Implants intended to stimulate or enhance the body's reparative response
- Multiple product strategies
 - Therapeutic protein growth factors (BMP, PDGF)
 - Demineralized bone (cadaveric source)
 - Synthetic/ceramics (resorbable calcium-based materials)
 - Viable cell products ("stem cell" products)
- >\$1.7B market segment, growing 5% annually

U.S. Orthopedic Biomaterials Market



Total Revenues (\$M)



Source: SmartTrak GPS

The Vivorté Difference



- Fragmented market = opportunity for Vivorté
 - Market has largely commoditized, poorly differentiated products
 - Surgeon misunderstanding and confusion on what "best" products are
 - Large orthopedic companies typically de-emphasize "biologics" selling relative to traditional hardware
- Vivorté Advantage:
 - R&D and commercial focus on biomaterials
 - Differentiated product with distinct clinical performance characteristics
 - Internal product expertise

Vivorté's product platform compares favorably to similar products from leading orthopedic companies

Vivorté Product Portfolio Summary



	TRABEXUS EB	FORTERA	REGENTO
Description	Moldable, curable, osteoinductive bone matrix [†]	Self-setting injectable cement	Particulate graft
Composition	Calcium phosphate with partially demineralized allograft	Calcium phosphate	β-tricalcium phosphate
Positioning	"All-in-one" graft: strength, bioactivity, resorbable	Highest strength, minimally invasive application	Bone void filler

Three distinct product lines to address unique clinical applications

[†] Allograft component demonstrated osteoinductivity in athymic mouse model submitted for 510(k). Refer to 510(k) summary K143547. Data on file at Vivorté, Inc.


Product Applications



Proximal Tibia Fracture



Calcaneus Fracture




Total Joint Revision

Vivorté products have been used in a wide array of clinical indications including fracture repair, fusions, reconstructive procedures, joint revisions, backfill procedures and orthopedic oncology

TRABEXUS EB Product Snapshot



- **Material**
 - Calcium phosphate cement
 - Partially demineralized bone – "TRABS[®]"
- **Design Rationale**
 - Resorbable, osteoconductive matrix
 - Partially demineralized, engineered bone component provides osteoinductivity
 - "Hourglass" shape optimizes interconnectivity and strength
 - TRABS provide resorption channels, accelerate remodeling
 - Faster resorption/remodeling relative to standard cement
- **Differentiating Aspects**
 - Proprietary design
 - Moldable, settable, highly-resorbable
 - Optimized ratio of compressive strength and allograft content



TRABEXUS EB Comparison



	TRABEXUS EB (Vivorté)	EquivaBone (ZimmerBiomet)
Calcium Phosphate (w/w)	82%	47.5%
Allograft (w/w)	18%	50%
Compressive Strength	20-25 MPa	1-2 MPa
Dimensional Stability (maintains volume and does not expand)	YES	NO
Resorption Profile	Faster	Slower


TRABEXUS EB has a lower allograft percentage, yet remodels more quickly and possesses higher compressive strength

Source: Data on file, EquivaBone sales literature

FORTERA Product Snapshot



- Fully synthetic composition
- Injectable up to 16 gauge
- Isothermic setting
- Solidifies into hydroxyapatite
- Superior compressive strength
- Does not require refrigeration prior to use




Up to **45MPa**
compressive strength

Source: Colon (2015), Dadkhah (2017); Data on file

REGENTO™ Bone Void Filler



- β -TCP (tri-calcium phosphate granules)
- Micro-porosity (300 micron) to promote protein deposition; cell attachment
- Osteoconductive scaffold, bone graft extender
- Can be combined with bone marrow aspirate or blood or saline
- Available in two particle size ranges:
 - 1,000-2,000 μ m (regular)
 - 2,000-3,250 μ m (large format)



Manufacturing/Supply Chain



- Vivorté maintains a FDA registered and ISO 13485 compliant manufacturing cleanroom facility for its bone grafting products
- Packaging, labeling, distribution, storage managed in-house
- Current capacity – >50,000 kits/year
- "TRAB" fabrication process know-how
- Vivorté maintains long-term supply agreements for key components of the proprietary calcium phosphate cement formulation



Corporate Details



- **Background**
 - Founded 2011, based in Louisville, Kentucky
 - Spinout from University of Louisville (U of L)
- **Financial**
 - Company primarily financed through angel investment, friends/family
 - Capital efficient, limited ownership dilution
- **Intellectual Property**
 - U.S. and worldwide patents under license from U of L
 - Process know-how and trade secrets

Recent Deal Comparables



Company	Technology	Deal Size	Multiple	Round	Stage	Date
BoneSupport	Hydroxyapatite/calcium sulfate injectable cements	\$60M (\$170M valuation)	13X	IPO	Commercial	Jun 2017
Xpand Biotechnology	Calcium phosphate biomaterials	\$40M	N/A	Acquisition	Commercial (EU)	Dec 2016
BioStructures	Synthetic and allograft products	\$81M	6X	Acquisition	Commercial	Oct 2015
Biom'Up	Surgical hemostats, bone void fillers	\$35M	N/A	Series C	Commercial (EU)	Sep 2015
Advanced Biologics	Enhanced demineralized bone matrix	\$38.5M	2X	Acquisition	Commercial	Oct 2014
ETEX	Calcium phosphate biomaterials	\$50M	4X	Acquisition	Commercial	Oct 2014

The logo features the word "Vivorté" in a bold, dark green, italicized sans-serif font. Below it, the tagline "strength for life" is written in a smaller, dark green, italicized serif font. The text is centered over a background of several concentric, light gray circles that create a ripple effect.

Vivorté

strength for life